Puma pharmaceutical's new drug, neratinib, did not perform as well as Herceptin in the latest clinical trials - by the definition of extending disease free survival.
However, bad news doesn't mean bad news when you look at the rest of the story.
"As expected, there was no statistically significant difference in
progression-free survival and objective response rate for the paclitaxel
plus neratinib arm compared to the paclitaxel plus trastuzumab arm,"
Auerbach said. "However ... while the development of other HER2-targeted
drugs has produced a clinically meaningful benefit to patients with
HER2 positive breast cancer, these drugs have had little impact on CNS
metastases. As a result, we believe that there remains an unmet clinical
need for reducing the incidence of CNS metastases, and the results of
the NEfERTT study demonstrate that we may be able to provide this type
of improvement with neratinib."
CNS metastases are Clinical Nervous System mets (I had to look that up). Which would really suck. So that means that while it did not extend disease free survival it did open a door to other advancements. So stay tuned, I guess, for the rest of the story. Or maybe this is just called progress.
I haven't been blogging recently because I have been emotionally stressed. It may take me a while longer to get back to it. My father , ...
As part of the universal pinkification of October, Good Housekeeping magazine has a section on breast cancer (who knew?). But one thing they...
About a year ago, I met a young woman who had had cancer since age 18 when she was diagnosed with an inherited pancreatic cancer. She had ne...
I often wonder in cancer treatment, which is worse - treatment or complications? I think complications win that one. To me complications mea...